After Achieving 52-Week High, Is Ligand Pharmaceuticals Incorporated (LGND)’s Near-Term Analysis Positive?

May 16, 2018 - By Orlando Souther

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Logo

Investors sentiment decreased to 1.25 in 2017 Q4. Its down 0.44, from 1.69 in 2017Q3. It fall, as 21 investors sold Ligand Pharmaceuticals Incorporated shares while 86 reduced holdings. 31 funds opened positions while 103 raised stakes. 22.68 million shares or 0.37% less from 22.76 million shares in 2017Q3 were reported.
44 are owned by Stratos Wealth Prns Ltd. 35,473 are held by Arizona State Retirement. First Mercantile reported 3,026 shares. 4,812 were reported by Fifth Third Comml Bank. Nuveen Asset Mngmt Ltd Liability Corp owns 0.01% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 9,251 shares. Riverhead Cap Mgmt Limited Liability holds 2,834 shares. 9,413 were accumulated by Cornerstone Cap Hldgs Limited Com. Sei Investments holds 10,857 shares. Northern Corporation holds 0.01% or 311,584 shares. Stephens Investment Mngmt Gru Ltd holds 429,734 shares. Eqis Capital Mngmt Inc stated it has 0.06% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Dupont Capital Management Corporation stated it has 0.04% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Bessemer Gru Inc owns 6,200 shares. Deutsche Financial Bank Ag has 471,203 shares. Bank Of Ny Mellon Corporation reported 526,411 shares stake.

Since December 20, 2017, it had 0 insider purchases, and 13 insider sales for $17.77 million activity. On Monday, April 2 KOZARICH JOHN W sold $401,063 worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) or 2,500 shares. The insider FOEHR MATTHEW W sold 8,881 shares worth $1.49 million. Sabba Stephen L sold 925 shares worth $126,956. Davis Todd C also sold $2.62M worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Monday, February 26. 3,335 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) shares with value of $536,604 were sold by LAMATTINA JOHN L. 3,417 shares were sold by Aryeh Jason, worth $529,635 on Friday, February 23.

The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) hit a new 52-week high and has $207.11 target or 9.00 % above today’s $190.01 share price. The 8 months bullish chart indicates low risk for the $4.05 billion company. The 1-year high was reported on May, 16 by Barchart.com. If the $207.11 price target is reached, the company will be worth $364.23M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 2.50% or $4.64 during the last trading session, reaching $190.01. About 247,774 shares traded. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has risen 53.11% since May 16, 2017 and is uptrending. It has outperformed by 41.56% the S&P500.

Analysts await Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to report earnings on August, 6. They expect $0.82 EPS, up 51.85 % or $0.28 from last year’s $0.54 per share. LGND’s profit will be $17.47M for 57.93 P/E if the $0.82 EPS becomes a reality. After $1.38 actual EPS reported by Ligand Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -40.58 % negative EPS growth.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Ratings Coverage

Among 5 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 4 have Buy rating, 1 Sell and 0 Hold. Therefore 80% are positive. Ligand Pharmaceuticals has $200.0 highest and $162.0 lowest target. $163.80’s average target is -13.79% below currents $190.01 stock price. Ligand Pharmaceuticals had 7 analyst reports since November 20, 2017 according to SRatingsIntel. The company was downgraded on Monday, November 20 by Deutsche Bank. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, January 24. The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) earned “Buy” rating by Stephens on Thursday, February 22. Craig Hallum maintained it with “Buy” rating and $200.0 target in Wednesday, March 7 report. The firm earned “Buy” rating on Thursday, February 22 by Craig Hallum. On Monday, February 26 the stock rating was maintained by Roth Capital with “Buy”. H.C. Wainwright maintained the shares of LGND in report on Wednesday, March 7 with “Buy” rating.

More notable recent Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) news were published by: Businesswire.com which released: “Ligand Reports First Quarter 2018 Financial Results” on May 08, 2018, also Streetinsider.com with their article: “Ligand Pharma (LGND) PT Raised to $119 at Deutsche Bank” published on May 09, 2018, Globenewswire.com published: “New Research Coverage Highlights Assurant, Williams Partners, Atmos Energy, Nationstar Mortgage, Applied …” on May 15, 2018. More interesting news about Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) were released by: Streetinsider.com and their article: “Ligand Pharma (LGND) Tops Q1 EPS by 40c” published on May 08, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Valeant Earnings, Lipocine’s FDA Watch, Invivo CFO Departure” with publication date: May 08, 2018.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company has market cap of $4.05 billion. The Company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. It has a 358.51 P/E ratio. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Science

Deepwater discovery in Mexican Gulf by Shell

Deepwater discovery in Mexican Gulf by Shell

Kelly Oliver

Recently one of the biggest oil companies in the world Shell has made big exploration of deep waters in the Gulf of Mexico. Researching took place 13 miles from Appomattox Shell’s project, which will start its production in the 2019 year, according to previous plans. Receive News & Ratings Via Email - ...

New recycling program for Boise

New recycling program for Boise

Ellis Scott

The new program is called Hefty EnergyBag Program. It was recently announced in Boise. Although it was made for help with recycling, there is confusion and many questions about it. Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news ...

Smart countryside as the key to the future

Smart countryside as the key to the future

Edwin Martin

So-called “smart cities” are usually taken as an example of the future for cities. The rise in the capacity for more information can help us to solve problems on the environmental and human scale. It will be possible with saving of energy and traffic regulations. Receive News & Ratings Via Email - ...

Pollution in the real-time observation

Pollution in the real-time observation

Dolores Ford

New technology made in Utah can provide the results of pollution in the real time. It can be used by environmental researchers who want to receive a clear view of toxins in the air. Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary ...

The red tape for commercial space flight is cut by Donald Trump

The red tape for commercial space flight is cut by Donald Trump

Darrin Black

Donald Trump, the 45th current president of the USA, wants commercial flight into space get real. He looks for boosting of space flights before it can be done by China. Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news ...

Thomas Hertog talks about his collaboration with Stephen Hawking

Thomas Hertog talks about his collaboration with Stephen Hawking

Thomas Roop

Thomas Hertog, the theoretical physicist told the press about his experience from the work with Stephen Hawking, his implication on Hertog’s new ideas, and their collaboration. Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with ...

Doubts behind Electromagnetic Drive Space Thruster Impossible from NASA

Doubts behind Electromagnetic Drive Space Thruster Impossible from NASA

Thomas Roop

While NASA celebrates its new creation, some experts believe it can’t work because of simple violations of the third law of Newton. It was called Impossible after it broke this law. However, further experiments show that it could have happened only because of errors in previous tests. Receive News & Ratings Via ...

New species in 2018

New species in 2018

Peter Erickson

ESF names animals, plants, and microbes that were able to survive instead of all predictions. There are big, small, beautiful, and weird. They have different groups, they are different species and even from different kingdoms. They are all united by their ability to survive and be discovered by scientists. Receive News & ...

Small helicopter on Mars

Small helicopter on Mars

Paul Bridgeforth

There will be a new feature for Mars of 2020. This invention is compared to the bold experiment of Wright Brothers almost 117 years ago. While they have shown that people can fly on Earth, the new invention will make flights possible on Mars. Receive News & Ratings Via Email - Enter ...

New El Niño is coming in 2018

New El Niño is coming in 2018

Orlando Souther

It predicts more natural disasters and unexpected weather conditions for the next year. Researchers say that there will be wildfires, droughts, and scorching temps for the next 12 months. Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and ...